Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorRodriguez-Urretavizcaya, Barbara
dc.contributor.authorPascual, Nuria
dc.contributor.authorPastells, Carme
dc.contributor.authorMartin Gomez, M Teresa
dc.contributor.authorVilaplana, Lluïsa
dc.contributor.authorMarco, Maria-Pilar
dc.date.accessioned2022-06-08T09:38:22Z
dc.date.available2022-06-08T09:38:22Z
dc.date.issued2021-12
dc.identifier.citationRodriguez-Urretavizcaya B, Pascual N, Pastells C, Martin-Gomez MT, Vilaplana L, Marco MP. Diagnosis and Stratification of Pseudomonas aeruginosa Infected Patients by Immunochemical Quantitative Determination of Pyocyanin From Clinical Bacterial Isolates. Front Cell Infect Microbiol. 2021 Dec;11:786929.
dc.identifier.issn2235-2988
dc.identifier.urihttp://hdl.handle.net/11351/7640
dc.descriptionPseudomonas aeruginosa; Monoclonal antibody; Pyocyanin
dc.description.abstractThe development of a highly sensitive, specific, and reliable immunochemical assay to detect pyocyanin (PYO), one of the most important virulence factors (VFs) of Pseudomonas aeruginosa, is here reported. The assay uses a high-affinity monoclonal antibody (mAb; C.9.1.9.1.1.2.2.) raised against 1-hydroxyphenazine (1-OHphz) hapten derivatives (PC1; a 1:1 mixture of 9-hydroxy- and 6-hydroxy-phenazine-2-carobxylic acids). Selective screening using PYO and 1-OHphz on several cloning cycles allowed the selection of a clone able to detect PYO at low concentration levels. The microplate-based ELISA developed is able to achieve a limit of detection (LoD) of 0.07 nM, which is much lower than the concentrations reported to be found in clinical samples (130 μM in sputa and 2.8 μM in ear secretions). The ELISA has allowed the investigation of the release kinetics of PYO and 1-OHphz (the main metabolite of PYO) of clinical isolates obtained from P. aeruginosa-infected patients and cultured in Mueller-Hinton medium. Significant differences have been found between clinical isolates obtained from patients with an acute or a chronic infection (~6,000 nM vs. ~8 nM of PYO content, respectively) corroborated by the analysis of PYO/1-OHphz levels released by 37 clinical isolates obtained from infected patients at different stages. In all cases, the levels of 1-OHphz were much lower than those of PYO (at the highest levels 6,000 nM vs. 300 nM for PYO vs. 1-OHphz, respectively). The results found point to a real potential of PYO as a biomarker of P. aeruginosa infection and the possibility to use such VF also as a biomarker for patient stratification[2] and for an effective management of these kinds of infections.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Cellular and Infection Microbiology;11
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMalalties bacterianes gramnegatives
dc.subjectPseudomones aeruginosa - Diagnòstic
dc.subject.meshPseudomonas Infections
dc.subject.mesh/diagnosis
dc.subject.meshPyocyanine
dc.titleDiagnosis and Stratification of Pseudomonas aeruginosa Infected Patients by Immunochemical Quantitative Determination of Pyocyanin From Clinical Bacterial Isolates
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fcimb.2021.786929
dc.subject.decsinfecciones por Pseudomonas
dc.subject.decs/diagnóstico
dc.subject.decspiocianina
dc.relation.publishversionhttps://doi.org/10.3389/fcimb.2021.786929
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Rodriguez-Urretavizcaya B, Pascual N, Pastells C, Vilaplana L, Marco MP] Nanobiotechnology for Diagnostics (Nb4D), Institute of Advanced Chemistry of Catalonia, Institute for Advanced Chemistry of Catalonia (IQAC)-Spanish National Research Council (CSIC), Barcelona, Spain. Centro de Investigación Biomédica en Red (CIBER) de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain. [Martin-Gomez MT] Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid34970510
dc.identifier.wos000743858100001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record